Home
MYGN
MYGN News

Latest Myriad Genetics Inc. (MYGN) News on November 17, 2024

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

Zacks

3 days ago

MYGN Stock Might Gain From SneakPeek Availability in Retail Stores

MT Newswires

3 days ago

Myriad Genetics Says Fetal Gender Test Available at Over 8,000 Stores in US

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

GlobeNewswire

4 days ago

Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch

Argus Research

4 days ago

MYGN: Lowering target price to $13.00

Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

8 days ago

Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Zacks

9 days ago

MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View

Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...

GuruFocus.com

9 days ago

Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ...

Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics

Zacks

9 days ago

Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics

Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates

Zacks

9 days ago

Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates

Associated Press Finance

9 days ago

Myriad: Q3 Earnings Snapshot

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

GlobeNewswire

9 days ago

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Zacks

10 days ago

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Argus Research

11 days ago

MYGN: Lowering target price to $14.00

MT Newswires

12 days ago

Myriad Genetics Disputes Inclusion of GeneSight in UnitedHealthcare's Coverage Restriction

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

GlobeNewswire

13 days ago

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

Myriad weakness due to UnitedHealth coverage update, says Stephens

TipRanks

14 days ago

Myriad weakness due to UnitedHealth coverage update, says Stephens

Morningstar Research

15 days ago

Analyst Report: Myriad Genetics, Inc.

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire

18 days ago

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Zacks

19 days ago

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Morningstar Research

25 days ago

Analyst Report: Myriad Genetics, Inc.

Myriad Genetics Shares Fall Despite Partnership With jscreen

Zacks

a month ago

Myriad Genetics Shares Fall Despite Partnership With jscreen

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

GlobeNewswire

a month ago

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

GlobeNewswire

a month ago

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week

Simply Wall St.

a month ago

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests

Zacks

a month ago

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests

Myriad signs five partnerships to study MRD testing in breast cancer

Clinical Trials Arena

a month ago

Myriad signs five partnerships to study MRD testing in breast cancer

Argus Research

a month ago

MYGN: What does Argus have to say about MYGN?

MT Newswires

a month ago

Myriad Genetics Outlines Five Projects on Studying Breast Cancer Test

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

GlobeNewswire

a month ago

Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer

Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests

Medical Device Network

a month ago

Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests

MT Newswires

a month ago

Myriad Genetics, Ultima Genomics Collaborate to Explore UG 100 Sequencing Platform

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

GlobeNewswire

a month ago

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

MT Newswires

2 months ago

Myriad Genetics Gets Third Patent for Molecular Residual Disease Assay

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

GlobeNewswire

2 months ago

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

BMRN or MYGN: Which Is the Better Value Stock Right Now?

Zacks

2 months ago

BMRN or MYGN: Which Is the Better Value Stock Right Now?

Morningstar Research

2 months ago

Analyst Report: Myriad Genetics, Inc.

MT Newswires

2 months ago

Myriad Genetics Has Many Opportunities for Growth, Needs Sustained Execution, Morgan Stanley Says

MT Newswires

2 months ago

Update: Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target

MT Newswires

2 months ago

Morgan Stanley Initiates Myriad Genetics at Equalweight

Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock

Zacks

2 months ago

Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

GlobeNewswire

2 months ago

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Should You Continue to Retain MYGN Stock in Your Portfolio?

Zacks

2 months ago

Should You Continue to Retain MYGN Stock in Your Portfolio?

Morningstar Research

2 months ago

Analyst Report: Myriad Genetics, Inc.

Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

2 months ago

Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)

Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

2 months ago

Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN)

MT Newswires

2 months ago

Myriad Genetics Insider Sold Shares Worth $400,800, According to a Recent SEC Filing

Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

2 months ago

Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN)

MT Newswires

2 months ago

Myriad Genetics Insider Sold Shares Worth $270,520, According to a Recent SEC Filing

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Zacks

2 months ago

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Myriad Genetics to Host Investor Event on October 9, 2024

GlobeNewswire

2 months ago

Myriad Genetics to Host Investor Event on October 9, 2024

MT Newswires

2 months ago

Myriad Genetics Insider Sold Shares Worth $1,285,851, According to a Recent SEC Filing

Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

2 months ago

Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN)

Morningstar Research

2 months ago

Analyst Report: Myriad Genetics, Inc.

MT Newswires

2 months ago

Myriad Genetics Discontinues Analysis on GeneSight Testing Due to Control Group Disparities

New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues

Zacks

2 months ago

New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

Zacks

3 months ago

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term

MT Newswires

3 months ago

Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target

Argus Research

3 months ago

MYGN: Lowering target price to $23.00

Insider Sale at Myriad Genetics Inc (MYGN): SVP, Chief of Staff Margaret Ancona Sells Shares

GuruFocus.com

3 months ago

Insider Sale at Myriad Genetics Inc (MYGN): SVP, Chief of Staff Margaret Ancona Sells Shares

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

GlobeNewswire

3 months ago

Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Argus Research

3 months ago

MYGN: What does Argus have to say about MYGN?

Insider Sale: Director Rashmi Kumar Sells 7,500 Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

3 months ago

Insider Sale: Director Rashmi Kumar Sells 7,500 Shares of Myriad Genetics Inc (MYGN)

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Morningstar Research

3 months ago

Analyst Report: Myriad Genetics, Inc.

Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised

Zacks

3 months ago

Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised

Myriad Genetics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

Myriad Genetics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Morningstar Research

3 months ago

Analyst Report: Myriad Genetics, Inc.

MT Newswires

3 months ago

Myriad Genetics Swings to Q2 Adjusted Profit, Sales Jump; Lifts 2024 Guidance

Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

3 months ago

Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates

Zacks

3 months ago

Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates

Associated Press Finance

3 months ago

Myriad: Q2 Earnings Snapshot

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

GlobeNewswire

3 months ago

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

GlobeNewswire

3 months ago

Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

GlobeNewswire

4 months ago

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

GlobeNewswire

4 months ago

Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024

Argus Research

4 months ago

MYGN: What does Argus have to say about MYGN?

INCY or MYGN: Which Is the Better Value Stock Right Now?

Zacks

4 months ago

INCY or MYGN: Which Is the Better Value Stock Right Now?

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

GlobeNewswire

4 months ago

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

Argus Research

4 months ago

MYGN: Raising target price to $22.00

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

Zacks

4 months ago

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

MT Newswires

4 months ago

Myriad Genetics, Personalis to Cross-License IP on Minimal Residual Disease Tests

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

GlobeNewswire

4 months ago

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Zacks

4 months ago

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Argus Research

4 months ago

MYGN: What does Argus have to say about MYGN?

MT Newswires

4 months ago

Myriad Genetics Receives New US Patent for Molecular Residual Disease Technology

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

GlobeNewswire

4 months ago

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Morningstar Research

4 months ago

Analyst Report: Myriad Genetics, Inc.

Argus Research

4 months ago

MYGN: What does Argus have to say about MYGN?

Myriad Genetics Earns 2024 Great Place To Work® Certification™

GlobeNewswire

4 months ago

Myriad Genetics Earns 2024 Great Place To Work® Certification™

MT Newswires

5 months ago

Scotiabank Initiates Myriad Genetics at Sector Outperform

Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election

GlobeNewswire

5 months ago

Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 30% Undervalued

Simply Wall St.

5 months ago

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 30% Undervalued

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

Zacks

5 months ago

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

Zacks

5 months ago

Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

MT Newswires

5 months ago

Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

GlobeNewswire

5 months ago

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?

Zacks

5 months ago

Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?

Insider Sale: Director Daniel Spiegelman Sells Shares of Myriad Genetics Inc (MYGN)

GuruFocus.com

5 months ago

Insider Sale: Director Daniel Spiegelman Sells Shares of Myriad Genetics Inc (MYGN)

Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

GlobeNewswire

5 months ago

Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

GlobeNewswire

5 months ago

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

Share on Social Networks: